Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab.

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...